Immutep reports encouraging disease-free survival from the EFTISARC-NEO Phase II trial in soft tissue sarcoma.
Immutep reports encouraging disease-free survival from the EFTISARC-NEO Phase II trial in soft tissue sarcoma.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in